Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | PRNP | P04156 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.51 |
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203976 | 0.89 | HPGDS (0.60) | PTPN1PRNPKMT2AMEN1HPGDS | |
| SCHEMBL4837018 | 0.85 | PRNP (0.54) | PTPN1PRNPKMT2AMEN1HPGDS | |
| SCHEMBL27871000 | 0.83 | KMT2A (0.61) | PTPN1PRNPKMT2AMEN1HPGDS | |
| SCHEMBL14380710 | 0.83 | PRNP (0.53) | PTPN1PRNPKMT2AMEN1HPGDS | |
| SCHEMBL29758522 | 0.79 | PTPN1 (0.57) | PTPN1KMT2AMEN1HPGDSMAPT | |
| SCHEMBL166468 | 0.79 | PTPN1 (0.57) | PTPN1KMT2AMEN1HPGDSMAPT | |
| SCHEMBL8740774 | 0.79 | PTPN1 (0.57) | PTPN1KMT2AMEN1HPGDSMAPT | |
| SCHEMBL4104266 | 0.79 | PTPN1 (0.62) | PTPN1KMT2AHPGDSGSK3BALDH1A1 | |
| SCHEMBL9547639 | 0.79 | PTPN1 (0.62) | PTPN1KMT2AMEN1HPGDSMAPT | |
| SCHEMBL30752696 | 0.78 | PTPN1 (1.00) | PTPN1KMT2AMEN1HPGDSMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2682393-A1 | Inhibitors of HCV NS5A comprising a bicyclic core. | Presidio Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20050176791-A1 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20040010022-A1 | 5-HT2B receptor antagonists | ASTERAND, INC. | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | PTPN1 2006/4885PRNP 2663/4885KMT2A 2279/4885 |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PTPN1 207/4885PRNP 905/4885KMT2A 4270/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PTPN1 202/4885PRNP 894/4885KMT2A 4293/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PTPN1 202/4885PRNP 894/4885KMT2A 4293/4885 |
| US-20050176791-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR3B | PTPN1 1621/4885PRNP 2489/4885KMT2A 3721/4885 |
| US-20040010022-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR2C | PTPN1 2159/4885PRNP 3232/4885KMT2A 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.